James Randall, MD
Hematology & Oncology · San Diego, CANPI 1144407115
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,131 of the $1,526 with a category attached, or 74.1%. 14 manufacturers reported payments, led by Exelixis Inc. at 39.8% of the total. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 65 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$607
- Merck$220
- AVEO Pharmaceuticals, Inc.$184
- AstraZeneca$118
- Dendreon Pharmaceuticals LLC$63
- Bayer$59
- plus $274 from 8 others
Across 44 payments — averaging $22,529 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$649K
- Astellas Pharma Global Development$197K
- Genentech, Inc.$46K
- Pharmacyclics LLC, An Abbvie Company$43K
- E.r. Squibb & Sons, L.L.C.$23K
- Ferring Pharmaceuticals AS$16K
- plus $17K from 3 others
What the payments were for
- Food & beverage$1,13174%
- Education$39526%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 36 | $607 |
| Merck | 5 | $220 |
| AVEO Pharmaceuticals, Inc. | 2 | $184 |
| AstraZeneca | 6 | $118 |
| Dendreon Pharmaceuticals LLC | 2 | $63 |
| Bayer | 3 | $59 |
| Tempus AI, Inc | 2 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $54 |
| Eisai Inc. | 2 | $41 |
| 180 Medical, Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $28 |
| Astellas Pharma US Inc | 1 | $24 |
| Novartis | 1 | $22 |
| Blue Earth Diagnostics | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$101
How this compares
$1,526 in reported general payments places this provider in the 35th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 76 | $1,048,238 |
| NubeqaDarolutamide | 76 | $876,180 |
| CabometyxCabozantinib S-Malate | 24 | $553,869 |
| Abiraterone Acetate | 266 | $421,390 |
| XtandiEnzalutamide | 27 | $314,326 |
| OrgovyxRelugolix | 91 | $239,840 |
| LynparzaOlaparib | 11 | $158,591 |
| SutentSunitinib Malate | 11 | $107,870 |
| Nilutamide | 17 | $55,328 |
| EliquisApixaban | 44 | $30,908 |
| Prednisone | 376 | $1,380 |
| Tamsulosin Hcl | 84 | $1,073 |
| Dexamethasone | 35 | $419 |
| Prochlorperazine Maleate | 22 | $374 |
| Finasteride | 18 | $318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $28 | $1,048,23876 claims |
| BayerNubeqa | $59 | $876,18076 claims |
| Exelixis Inc.Cabometyx | $607 | $553,86924 claims |
| Astellas Pharma US IncXtandi | $24 | $314,32627 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $54 | $239,84091 claims |
| AstraZenecaLynparza | $118 | $158,59111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in San Diego
- Wendy LevinSan Diego$760K
- Rana McKaySan Diego$530K
- Ezra CohenSan Diego$495K
- Annette von DrygalskiSan Diego$406K
- Lyudmila BazhenovaSan Diego$328K
- Sandip PatelSan Diego$295K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.